|
1
|
Péron J, Bylicki O, Laude C, Martel-Lafay
I, Carrie C and Racadot S: Nonoperative management of squamous-cell
carcinoma of the rectum. Dis Colon Rectum. 58:60–64. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeong BG, Kim DY and Kim SY: Concurrent
chemoradiotherapy for squamous cell carcinoma of the rectum.
Hepatogastroenterology. 60:512–516. 2013.PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Musio D, De Felice F, Manfrida S, Balducci
M, Meldolesi E, Gravina GL, Tombolini V and Valentini V: Squamous
cell carcinoma of the rectum: The treatment paradigm. Eur J Surg
Oncol. 41:1054–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagpal K and Bennett N: Colorectal surgery
and its impact on male sexual function. Curr Urol Rep. 14:279–284.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rouanet P, Mourregot A, Azar CC, Carrere
S, Gutowski M, Quenet F, Saint-Aubert B and Colombo PE: Transanal
endoscopic proctectomy: An innovative procedure for difficult
resection of rectal tumors in men with narrow pelvis. Dis Colon
Rectum. 56:408–415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hendren S and Fiscella K: Patient
navigation improves the care experience for patients with newly
diagnosed cancer. J Clin Oncol. 32:3–4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moran MS, Schnitt SJ, Giuliano AE, Harris
JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G,
Houssami N, et al: Society of Surgical Oncology-American Society
for Radiation Oncology consensus guideline on margins for
breast-conserving surgery with whole-breast irradiation in stages I
and II invasive breast cancer. Int J Radiat Oncol Biol Phys.
88:553–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Specht L, Yahalom J, Illidge T, Berthelsen
AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel
NG, et al: ILROG: Modern radiation therapy for Hodgkin lymphoma:
Field and dose guidelines from the international lymphoma radiation
oncology group (ILROG). Int J Radiat Oncol Biol Phys. 89:854–862.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thuss-Patience PC, Hofheinz RD, Arnold D,
Florschütz A, Daum S, Kretzschmar A, Mantovani-Löffler L, Bichev D,
Breithaupt K, Kneba M, et al: Perioperative chemotherapy with
docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal
adenocarcinoma: A phase II study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO){dagger}. Ann Oncol. 23:2827–2834.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A
randomized, multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol.
32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai Q, Avolio AW, Graziadei I, Otto G,
Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB and Lerut J:
European Hepatocellular Cancer Liver Transplant Study Group:
Alpha-fetoprotein and modified response evaluation criteria in
solid tumors progression after locoregional therapy as predictors
of hepatocellular cancer recurrence and death after
transplantation. Liver Transpl. 19:1108–1118. 2013.PubMed/NCBI
|
|
13
|
Marks J, Nassif G, Schoonyoung H, DeNittis
A, Zeger E, Mohiuddin M and Marks G: Sphincter-sparing surgery for
adenocarcinoma of the distal 3 cm of the true rectum: Results after
neoadjuvant therapy and minimally invasive radical surgery or local
excision. Surg Endosc. 27:4469–4477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muro K: Systemic chemotherapy for
metastatic colorectal cancer - Japanese Society for Cancer of the
Colon and Rectum (JSCCR) Guidelines 2016 for treatment of
colorectal cancer. Nihon Shokakibyo Gakkai Zasshi. 114:1217–1223.
2017.PubMed/NCBI
|
|
15
|
Rödel C, Graeven U, Fietkau R, Hohenberger
W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA,
Lang-Welzenbach M, et al: German Rectal Cancer Study Group:
Oxaliplatin added to fluorouracil-based preoperative
chemoradiotherapy and postoperative chemotherapy of locally
advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final
results of the multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 16:979–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
André T, de Gramont A, Vernerey D,
Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T,
Tabernero J, Van Laethem JL, et al: Adjuvant fluorouracil,
leucovorin, and oxaliplatin in stage II to III colon cancer:
Updated 10-year survival and outcomes according to BRAF mutation
and mismatch repair status of the MOSAIC study. J Clin Oncol.
33:4176–4187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ,
Park YS, Park JO, Kim SY, Kim TY, Kim JH, et al: Oxaliplatin,
fluorouracil, and leucovorin versus fluorouracil and leucovorin as
adjuvant chemotherapy for locally advanced rectal cancer after
preoperative chemoradiotherapy (ADORE): An open-label, multicentre,
phase 2, randomised controlled trial. Lancet Oncol. 15:1245–1253.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai X, Zhang X, Wang C, Jiang J and Wu C:
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus
S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer
patients. Oncotarget. 8:30495–30501. 2017.PubMed/NCBI
|
|
19
|
Xiao H, Xiong L, Song X, Jin P, Chen L,
Chen X, Yao H, Wang Y and Wang L: Angelica sinensis polysaccharides
ameliorate stress-induced premature senescence of hematopoietic
cell via protecting bone marrow stromal cells from oxidative
injuries caused by 5-fluorouracil. Int J Mol Sci. 18:182017.
View Article : Google Scholar
|
|
20
|
Lee EM, Hong YS, Kim KP, Lee JL, Kim SY,
Park YS, Choi DH, Kim JH, Lim SB, Yu CS, et al: Phase II study of
preoperative chemoradiation with S-1 plus oxaliplatin in patients
with locally advanced rectal cancer. Cancer Sci. 104:111–115. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang M, Lu X, Zhang C, Du C, Cao L, Hou T,
Li Z, Tu B, Cao Z, Li Y, et al: Downregulation of SIRT7 by
5-fluorouracil induces radiosensitivity in human colorectal cancer.
Theranostics. 7:1346–1359. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gheidari F, Bakhshandeh B,
Teimoori-Toolabi L, Mehrtash A, Ghadir M and Zeinali S: TCF4
silencing sensitizes the colon cancer cell line to oxaliplatin as a
common chemotherapeutic drug. Anticancer Drugs. 25:908–916. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amorim R, Pinheiro C, Miranda-Gonçalves V,
Pereira H, Moyer MP, Preto A and Baltazar F: Monocarboxylate
transport inhibition potentiates the cytotoxic effect of
5-fluorouracil in colorectal cancer cells. Cancer Lett. 365:68–78.
2015. View Article : Google Scholar : PubMed/NCBI
|
